You’re reading The Checkup With Dr. Wen, a newsletter on how to navigate medical and public health challenges. Click here to ...

The market has been swinging recently, with the S&P 500 index down 1.5% and the Nasdaq Composite down more than 2% over the ...

Health, a leader in virtual cardiometabolic care, today announced a new offering designed to make access to obesity management medications and care more sustainable for employers. The "No-Barriers ...

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma ...

The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...

In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...

Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid ...

The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with ...

Navigate insurance coverage for GLP-1 weight loss medications like Wegovy and Zepbound by learning about costs, eligibility requirements, prior authorizations, and appeals to maximize your chances of ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market ...

This expansion supports a strategic initiative to embed Eli Lilly within emerging biotechnology ecosystems. The Gateway Labs program provides promising startups with modern laboratory space and direct ...